6Indexed trials
drug · Product Intelligence
Topiramate
Pipeline Intelligence
Topiramate: 6 indexed trials, 3 sponsors; 11 linked Orange Book patents and 8 FDA-linked events where matched.
3Sponsors
11Orange Book patent links
8FDA-linked events
Development evidence
NCT00236743Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · epilepsyPHASE3
NCT00236847Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · epilepsyPHASE2
NCT00236860Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · epilepsyPHASE2
NCT00266604Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · epilepsyPHASE4
NCT00297349Janssen Cilag Pharmaceutica S.A.C.I., Greece · epilepsyCOMPLETED
NCT02878798Virginia Commonwealth University · pain_neuropathyPHASE2
FDA / patent evidence
10363224QUDEXY XR · app 2051222033-03-19
8652527QUDEXY XR · app 2051222033-03-19
8889190QUDEXY XR · app 2051222033-03-19
9101545QUDEXY XR · app 2051222033-03-19
9555005QUDEXY XR · app 2051222033-03-19
8580299QSYMIA · app 0225802029-06-14
8580298QSYMIA · app 0225802029-05-15
8895057QSYMIA · app 0225802028-06-09
8895058QSYMIA · app 0225802028-06-09
9011905QSYMIA · app 0225802028-06-09
9011906QSYMIA · app 0225802028-06-09
Regulatory context
FDA_EXCLUSIVITYQSYMIA · M-3082027-09-13
FDA_APPROVALTOPIRAMATE · 2024-07-11
FDA_APPROVALQUDEXY XR · 2014-03-11
FDA_APPROVALTOPIRAMATE · 2013-02-27
FDA_APPROVALQSYMIA · 2012-07-17
FDA_APPROVALTOPIRAMATE · 2009-04-15
FDA_APPROVALTOPIRAMATE · 2009-03-27
FDA_APPROVALTOPIRAMATE · 2009-03-27
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.